University of the Incarnate Word

The Athenaeum
Doctor of Nursing Practice
12-2017

Implementing Evidence-based Opioid Prescription Practices In a
Primary Care Setting
Cyril Gaiennie
University of the Incarnate Word, trey.gaiennie@gmail.com

Follow this and additional works at: https://athenaeum.uiw.edu/uiw_dnp
Part of the Family Medicine Commons, Family Practice Nursing Commons, Internal Medicine
Commons, Preventive Medicine Commons, Primary Care Commons, and the Substance Abuse and
Addiction Commons

Recommended Citation
Gaiennie, Cyril, "Implementing Evidence-based Opioid Prescription Practices In a Primary Care Setting"
(2017). Doctor of Nursing Practice. 14.
https://athenaeum.uiw.edu/uiw_dnp/14

This Doctoral Project is brought to you for free and open access by The Athenaeum. It has been accepted for
inclusion in Doctor of Nursing Practice by an authorized administrator of The Athenaeum. For more information,
please contact athenaeum@uiwtx.edu.

Running head: IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION PRACTICES IN A
PRIMARY CARE SETTING
by
CYRIL C GAIENNIE III

DNP PROJECT ADVISOR/CLINCAL MENTOR:
_______________________________________
Jean Dowling Dols PhD, RN, NEA-BC, FACHE

______________________________________
John Dickson MD

1

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

Copyright by
Cyril Gaiennie
2017

2

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

3

Acknowledgements
I would like to thank Dr. Jean Dols, my project advisor, for her clear guidance,
encouragement, and truly remarkable support not only throughout this project, but also
throughout my entire journey. Her expertise, attention to detail, and knowledge has been
inspiring and has helped me push through to complete this project. Her dedication to the success
of all she teaches continues to motivate me to strive to accomplish more than I thought possible.
To my wonderful loving wife and best friend Shari, thank you for the love,
encouragement, and support. You are the best part of the journey. You encouraged me to eat the
elephant one bite at a time, and you were right. Thank you for being mine.

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

4

Table of Contents
LIST OF TABLES ..........................................................................................................................5
LIST OF FIGURES ........................................................................................................................6
ABSTRACT....................................................................................................................................7
STATEMENT OF THE PROBLEM ..............................................................................................9
ASSESSMENT ..............................................................................................................................10
Readiness for Change ........................................................................................................12
PROJECT AIM ..............................................................................................................................12
SUMMARY AND STRENGTH OF THE EVIDENCE ...............................................................13
METHODS.....................................................................................................................................16
Project Intervention............................................................................................................16
Barriers and Facilitators .....................................................................................................19
RESULTS ......................................................................................................................................20
DISCUSSION ................................................................................................................................29
LIMITATIONS ..............................................................................................................................31
Recommendations ..............................................................................................................32
Implications for Practice ....................................................................................................32
CONCLUSION ..............................................................................................................................33
REFERENCES ..............................................................................................................................34

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

5

List of Tables
Table

Page

1. Characteristics of Pre-intervention Patient Population ............................................................11
2. Roles and Responsibilities .......................................................................................................18
3. Project Objectives ....................................................................................................................19
4. Fisher’s exact test: Relationship between implementation of all six of the CDC guidelines
and referral to pain management..............................................................................................22
5. Chi-square: Relationship between implementation of all six of the CDC guidelines and
number of opioid prescriptions written ....................................................................................23
6. Chi-square: Relationship between utilization of the PDMP and receiving an opioid
medication prescription............................................................................................................24
7. Fisher’s exact test: Relationship between utilization of the PDMP and referral to pain
management for treatment of CNCP........................................................................................25
8. Chi-square: Relationship between utilization of the screening tool and receiving an opioid
medication prescription............................................................................................................26
9. Fisher’s exact test: Relationship between utilization of the screening tool and referral to pain
management for treatment of CNCP........................................................................................26
10. Fisher’s exact test: Relationship between utilization of urine drug screening and receiving an
opioid medication prescription ................................................................................................27
11. Fisher’s exact test: Relationship between depression and referral to pain management for
treatment of CNCP...................................................................................................................28
12. Fisher’s exact test: Relationship between depression and receiving an opioid medication
prescription ..............................................................................................................................29

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

6

List of Figures
Figure

Page

1. Pre- and Post-intervention utilization of CDC’s guidelines ......................................................21

IMPLEMENTING EVIDENCE-BASED OPIOID PRESCRIPTION

7

Abstract
The use and misuse of opioid pain medication has reached epidemic proportions in the
United States. More than 16,000 people die each year due to the misuse or abuse of prescription
opioid medications, which is more than from heroin, cocaine, and benzodiazepines combined.
The purpose of this evidence-based practice project is to establish processes enabling a primary
care clinic to implement and adhere to the 2016 Centers for Disease Control’s guidelines for
opioid prescription practices in the primary care setting. A retrospective chart review conducted
prior to implementation of the guidelines demonstrated that four of six of the CDC’s
recommendations were in place. Following the Centers for Disease Control guidelines, a process
was implemented to track evidence-based interventions including screening for potential abuse,
urine drug screening, patient education, provider assessment of need, accessing the prescription
drug monitoring program database, and the completion of a treatment agreement. Prior to
implementation, a retrospective chart study revealed that none of the patients were screened for
potential abuse, 80% had completed a treatment agreement, 90% had received education on
opioid medication and potential abuse, 75% had undergone urine drug screening, 5% had the
prescription drug monitoring program database accessed, and 95% had a documented provider
assessment of need for treatment. At the completion of the project, 82% of patients were
screened for potential abuse, 100% had completed a treatment agreement, 93% received
education on opioid abuse, 93% underwent urine drug screening, 68% had the prescription drug
monitoring program database accessed, and 96% had a documented provider assessment of need.
The implementation of these guidelines has led to 11 (7%) patients being referred to a pain
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management specialist and a 10% reduction in the number of prescriptions written for opioid
pain medications for patients seeking treatment for chronic pain.
Key words: Opioids; Primary Care; Chronic Non Cancer Pain; Prescription Drug Monitoring;
Guidelines
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Opioid prescription drug misuse has reached epidemic proportions in the United States.
Currently more people are killed overdosing on prescription opioid medications, than are killed
from heroin, cocaine, and benzodiazepines combined (Hawk, Vaca, & D’Onofrio, 2015; Chen et
al., 2016). In 2001, the Joint Commission established that pain was being undertreated and this,
as well as other factors, led to opioid pain medications being prescribed at alarming rates
(Broglio & Cole, 2014). The unintended consequences of the vast number of opioid prescriptions
being written include diversion, misuse, and abuse (Chen et al., 2016).
The costs to society in terms of dollars for lost productivity, losses due to crime, law
enforcement, and healthcare costs, exceed 400 billion annually (Substance Abuse and Mental
Health Services Administration [SAMHSA], 2016). Implementation of evidence-based
guidelines can help reduce the incidence of abuse and the risk of overdose, and may lead to
alternative medications and interventions for pain control.
Statement of the Problem
Each year over 100 million Americans will present to their primary care provider with a
complaint of pain, both chronic and acute (Compton, Boyle, & Wargo, 2015), while over 1,000
people each day will seek treatment in an emergency room for misusing prescription opioid
medications (SAMHSA, 2013). Chronic pain differs from acute pain and affects quality of life
and results in financial costs in excess of $560 billion annually for society in terms of lost wages,
healthcare costs, and lost productivity (Broglio & Cole, 2014; SAMHSA, 2016)). These patients
are complex and present with multiple medical and psychiatric comorbidities in addition to their
complaint of chronic non-cancer pain (CNCP) (Cheatle & Barker, 2014). Approximately 3.5% of
the adult population in the United States is prescribed opioid medications to treat CNCP
(Dowell, Haegerich, & Chou, 2016). Management of patients with CNCP is made more difficult
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because many providers do not have the training or tools needed to handle these complex
patients (Broglio & Cole, 2014). More than 16,000 people die each year (more than 43 per day),
due to the misuse or abuse of prescription opioid medications (Hawk et al, 2015; American
Public Health Association [APHA], 2015).
Assessment
A retrospective chart review of 157 adult patients diagnosed with chronic pain and
receiving opioid pain medications at the primary care clinic between January 1, 2017 and March
24, 2017 was conducted. This chart review demonstrated that 23% of the clinic patients being
prescribed opioid pain medication for CNCP were between 18 and 44 years of age, 55% were
between 45 and 64 years of age, and 22% were 65 years old or greater. These patients were 52%
male and 48% female and had an ethnic background of 20% Hispanic, 73% White non-Hispanic,
and 7% other. Patients with CNCP are more likely to have multiple chronic conditions (Cheatle
& Barker, 2014). In the pre-intervention assessment, 30% of the patients had one to three chronic
conditions, 50% were diagnosed with four to six chronic conditions, and 20% had seven or more
chronic conditions in addition to chronic pain (Table 1). The top chronic conditions for patients
in the pre-intervention chart review were; insomnia 37%, anxiety 48%, hypertension 42%,
hyperlipidemia 37%, constipation 31%, depression 20%, and ADHD 25% (Table 1). The current
practice in the clinic when prescribing opioid pain medications for patients with CNCP was to
obtain a treatment agreement, perform a urine drug screen, and educate patients on risks and
benefits of opioid pain medications. While these practices are included in the 2016 Centers for
Disease Control (CDC) guidelines for prescribing opioid medications for CNCP, several
additional practices needed to be added to the prescription process to be in compliance with the
recommendations including accessing the prescription drug-monitoring program (PDMP)
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database and screening for potential abuse. The clinic did not have a protocol or procedure to
ensure that all 2016 CDC guidelines were followed when prescribing opioid pain medications.
Table 1
Characteristics of Pre-intervention Patient Population
Category

Percentage

Sex
Male
Female

52%
48%

Race
Caucasian non-Hispanic
Hispanic
Other

73%
20%
7%

Age
18-44
45-64
65 and older

23%
55%
22%

Number of Chronic Conditions
1-3
4-6
7 or more

30%
50%
20%

Top Chronic Conditions
Hypertension
Hyperlipidemia
Constipation
ADHD
Depression
Insomnia

42%
37%
31%
25%
20%
38%
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Readiness for Change
A review of the 2016 CDC guidelines, current literature on the opioid prescription
medication epidemic, and the March 2017 retrospective chart review was shared with key
providers and resulted in a determination that the clinic was not aligned with the 2016 CDC
guidelines for prescribing opioid medications for CNCP. Prior to this review of the guidelines
and current literature, the clinicians and staff were unaware of the magnitude of morbidity and
mortality risk associated with prescription opioid misuse or abuse. Following this review of the
guidelines and the needs assessment, it was determined that an evidence-based project would be
implemented to help align the practice with all 2016 CDC guidelines for prescribing opioid
medications for CNCP. The available resources of the clinic were able to support this process
improvement project through the use of technology, training, space, and leadership.
Project Aim
The aim of this evidence-based practice project was to improve clinicians’ adherence to
the 2016 CDC guidelines on prescribing opioid pain medications for CNCP. The CDC guidelines
include assessment for need of opioid pain medication need, accessing the Prescription Drug
Monitoring Program (PDMP) database, completion of a treatment agreement that establishes
goals and ground rules, use of a screening tool to assess for potential misuse or abuse of
medications, screening urine for drugs, and patient education on opioid medications. The
objective of this evidence-based quality improvement project was to ensure adherence to the
guidelines to improve the quality of care patients receive.
To achieve the outlined objectives, the clinic implemented urine drug screening in
patients receiving opioid medications for CNCP, performed patient self screening with the
Screener and Opioid Assessment for Patients with Pain (SOAPP) Version 1.0-SF for abuse
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potential, checked the PDMP database, completed a treatment agreement, and received education
on opioid medications as outlined in the 2016 CDC guidelines (SOAPP, 2008). As a result of
implementing the CDC guidelines and improved prescription practices, the clinic identified
patients needing referral to a pain management clinic for treatment of their CNCP.
Summary and Strength of the Evidence
Prescription drug misuse and abuse is a growing problem in the United States. Nearly
100 million Americans present to their primary care physician with a complaint of chronic pain
(Compton et al., 2015) and it is estimated that 25.3 million adults suffer from chronic pain on a
daily basis (Philpot et al., 2017). Patients with CNCP are complex and present with multiple
medical and psychiatric comorbidities in the primary care setting (Cheatle & Barker, 2014).
Multiple comorbidities accompanied by chronic pain can make management of these patients
difficult in the primary care setting. Primary care providers are the dominant prescribers of
opioid pain medication for patients with CNCP, with more than 200 million prescriptions being
written annually (Broglio & Cole, 2014). In fact, primary care providers account for half of all
opioid prescriptions in the United States (Dowell et al., 2016). The massive prescribing of opioid
medications for pain has been associated with the unintended consequence of misuse and abuse
and associated morbidity and mortality (Broglio & Cole, 2014). Between 1999 and 2010, fatal
overdoses from opioid medications soared from 4,000 deaths to more than 16,000 annually
(Hawk et al., 2015). Since 2010 prescription opioid medications have caused more overdose
deaths than heroin and cocaine combined (APHA, 2015).
The CDC recommends that all patients being treated for CNCP receive a complete
assessment by a provider and complete a risk assessment that scores the patient’s potential for
misuse and abuse of opioid medications (Dowell et al., 2016). In addition, the CDC guidelines
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recommend urine drug screening, patient education, and the completion of a treatment agreement
prior to prescribing opioid pain medications for CNCP (Dowell et al., 2016). Accessing the
PDMP database is also highly recommended as a best practice to determine if patients are
physician shopping or filling prescriptions at multiple pharmacies (Dowell et al., 2016).
A comprehensive assessment of the patient is the first step in determining if opioid
medications are needed to treat the patient. Effects on quality of life, such as sleep, relationships,
activity level and emotions, as well as the quality of the pain along with aggravating or
alleviating factors involved should be documented as part of the assessment (Broglio & Cole,
2014). A thorough assessment can help to determine if the pain is nociceptive or neuropathic,
which will help determine the correct treatment regimen (Broglio & Cole, 2014). In addition to a
thorough provider assessment, the patient should complete a questionnaire that identifies the
potential for abuse or misuse of opioid medications. The Screener and Opioid Assessment for
Patients with Pain (SOAPP) version 1.0-SF is a tool for providers that can help determine patient
potential for abuse or misuse of opioid medication and helps determine how much monitoring a
patient on long-term opioid medication therapy might require (Screener and opioid assessment
for patients with pain [SOAPP], 2008). The SOAPP is a 5-question tool that with a sensitivity of
0.86 and a specificity of 0.67 indicating efficacy at identifying those at high risk for abuse, but
might include some who are truly low risk in the high risk category (SOAPP, 2008).
Information gained from the PDMP database can be invaluable in identifying those with
a high potential for abuse or misuse of opioid pain medications. Each PDMP database is
maintained individually by each state. The state regulatory agency that oversees pharmacists
administers the Texas PDMP. PDMP links clinicians to databases that help detect problem users,
diverters, and doctor shoppers (Compton et al., 2015). Use of PDMP leads to lower prescription
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rates and reduced rates of opioid poisoning (Haegerich, Paulozzi, Manns, & Jones, 2014). PDMP
databases are not a complete solution to the opioid pain medication misuse epidemic, they are an
important yet underutilized tool that has the potential to help save lives.
Urine drug screening is used to identify non-compliance, potential drug diversion, and
patient use of other drugs not currently prescribed (Volkow & McLellan, 2016). Urine drug
testing is the only objective measure to ensure the patient is taking the prescribed medication and
not taking illicit drugs or medications not prescribed (Broglio & Cole, 2014). The provider needs
to understand the capabilities and limitations of urine drug testing and tailor testing to meet the
needs of the patient and the situation, taking into account insurance coverage, results of previous
tests, and results of other tools used in the assessment of patients on opioid therapy for CNCP
(Broglio & Cole, 2014). At a minimum, random urine drug testing should happen un-announced
at least yearly, with additional testing taking place more often if the need for tighter oversight is
determined (Broglio & Cole, 2014; Dowell et al., 2016).
Informed consent and treatment agreements should be obtained prior to initiation of
opioid pain medication therapy for CNCP. Informed consent should outline the risks and benefits
of therapy, while the agreement should outline expectations for continued treatment at the clinic
(Nuckols et al., 2014). Safe use, disposal, pharmacy use, storage, disposal, and responsibilities of
the patient and provider should be addressed in any treatment agreement and discussed (Broglio
& Cole, 2014). Finally, education of the patient should take place to ensure complete
understanding of the reason for the opioid as well as the risks and benefits of opioid use.
Education topics should include multimodal therapy to reduce opioid use, improve pain control,
and enhance quality of life (Broglio & Cole, 2014). One-page handouts that discuss safe use,
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storage, disposal, and have a complete description of goals and expectations of pain management
should be provided to each patient (Broglio & Cole, 2014; Dowell et al., 2016).
Methods
Project Intervention
The setting for the project was a privately owned internal medicine practice located in
North Central San Antonio, Texas. The physician owner and 2 nurse practitioners staff the
practice. The providers currently serve 9,500 patients per year with 462 patients presenting with
complaints of chronic pain. Between January 1, 2017 and March 24, 2017, 157 patients were
treated for CNCP in the clinic. These 157 patients created 236 visits to the clinic between
January 1, 2017 and March 24, 2017. Of the 157 patients with CNCP; 23% were between 18 and
44 years of age, 55% were between 45 and 64 years of age, and 22% were 65 years old or
greater. The ethnic division of these patients was 20% Hispanic, 73% White non-Hispanic, and
7% other. In addition, 52% were male and 48% female. All patients and staff are primarily
English speaking with only one staff member fluent in Spanish.
The current practice in the clinic when prescribing opioid pain medications for patients
with CNCP was to obtain a treatment agreement, perform a urine drug screen, and educate
patients on risks and benefits of opioid pain medications. While these practices are included in
the 2016 Centers for Disease Control (CDC) (Dowell et al., 2016) guidelines for prescribing
opioid medications for CNCP, several additional practices needed to be added to the prescription
process to be in compliance with the guidelines. The clinic did not have a protocol or procedure
to ensure that all 2016 CDC guidelines were followed when prescribing opioid pain medications.
A pre-intervention chart audit was performed on 157 adult patients who had a diagnosis
of chronic pain and received opioid pain medications from the clinic between January 1, 2017
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and March 31, 2017. Data analysis, using IBM® SPSS® version 24, revealed that 95% of patients
received a provider assessment, 80% had completed a treatment agreement, 75% had undergone
urine drug screening prior to receiving the prescription, 90% had received education on opioid
medications, 5% had accessed the PDMP database, and none of the patients had completed a
screening tool (Table 3).
Pre-intervention activities included an information fair held in conjunction with a staff
lunch, training sessions, several quality meetings, and one on one informational sessions with
each staff member. Providers were given an application that could be installed on their smart
phone that included the guidelines, dosage calculations, and helpful information for prescribing
opioid medications. Providers were encouraged to complete an online training session provided
by the CDC that included information on best practices, the guidelines, preventing abuse, and
misuse of opioid medications. This online program was free of charge. Each staff member and
provider was provided with a copy of the current CDC guidelines, a copy of the screening tool
and instructions on how to score the tool, and a copy of the educational flyer provided by the
CDC at no charge. An interactive education session was conducted with all staff members and
providers to discuss the roles and responsibilities of each person during implementation of the
clinic’s opioid prescription practices. In addition, a meeting with providers was held to help them
register for access and learn how to use the PDMP database. Additional duties had to be
performed by different team members ensuring a successful implementation (Table 2).
The MAs now had additional responsibilities to ensure urine was collected on each
patient for testing, the screening tool was completed and placed on the chart for review by the
provider, the treatment agreement was completed and placed on the chart for review by the
provider, and to attend all quality meetings. The providers’ additional responsibilities included
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Table 2
Roles and Responsibilities
Intervention

Responsible Party

Staff Education

Project Leader

Education Pamphlet

Project Leader

Standing Orders

Physician Owner

Patient Assessments

Providers

Screening Tool (SOAPP) version 1.0-SF

MAs, reviewed by Provider

PDMP Database

Provider

Drug Screening

MAs

Treatment Agreement

MAs, reviewed by Provider

Quality Meetings

Project Leader

completing a needs assessments, completing physical and medical assessments of the patient,
accessing the PDMP, reviewing the screening tool and treatment agreement, and attending all
quality meetings. The project leader conducted staff education and provider education, held
quality meetings, disseminated information for all staff, and tracked adherence.
Upon evidence-based practice implementation, each patient presenting to the clinic with a
diagnosis of chronic pain received a treatment agreement form and screening tool form from the
receptionist. The receptionist instructed the patient to complete the treatment agreement and
screening tool while waiting to be taken back to the exam room. The MA called the patient back
and escorted them to the restroom where the patient provided a urine sample to undergo drug
screening to assess for compliance or abuse of other substances. The MA then escorted the
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patient to the exam room and started the intake process. The provider completed a

comprehensive assessment of the patient and their pain. This assessment was documented in the
Aprima® electronic medical record (EMR). The provider also accessed the PDMP to assess for
frequency of prescriptions, prescriptions from other providers, and to determine if other
controlled substances were currently being prescribed. The provider reviewed the screening tool
and initialed indicating review, reviewed the treatment agreement and initialed indicating review,
and provided education on opioid medications. All of this was documented by scanning into the
EMR or physically entered into the EMR. The provider then prescribed the best treatment
indicated for the patient.
Table 3
Project Objectives
Intervention

Current Adherence

Anticipated Adherence

Provider Assessment of Need

95%

95%

Screening Tool

0%

80%

Education

90%

90%

Access PDMP

5%

80%

Treatment Agreement

80%

80%

Urine Drug Screen

75%

80%

Barriers and Facilitators
The clinic faced many challenges prior to implementation of the new process. Barriers
included poor communication from providers to staff on expectations as most communication
happened in an informal way that could be ambiguous and confusing. Provider resistance was
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another barrier; change and new processes can be uncomfortable. In addition, familiarity with
the patients posed a barrier to utilization of the PDMP. A common theme in not accessing the
PDMP was “I know my patient so I do not need to look at that.” Patient resistance to undergoing
additional testing that might or might not be covered by insurance, additional forms to fill out,
and the general anxiety that comes from lab tests created a barrier to implementation. Finally, the
potential for lost income due to patients seeking treatment elsewhere is a barrier that could have
caused problems with implementation.
Facilitators included the physician owner who was committed to the project and wanted
the clinic to adhere to best practices. The staff were great facilitators due to low turnover and the
relationships they had with the patients of the clinic. The CDC guidelines set clear standards and
recommendations that would not add additional cost to clinic operations. Another factor that
helped facilitate implementation was the amount of news pertaining to the topic of misuse and
abuse of opioid prescription medications, including an article on a provider who was charged
with 5 counts of murder for over prescribing opioid medications ("Doctor charged with murder,”
2017). Sharing current stories on the costs associated with opioid medications helped to motivate
the staff and providers to ensure best practices. Finally, the clinic already was doing several of
the interventions contained in the guidelines; therefore adding two more interventions was not an
undue burden to the system.
Results
150 unique patients were seen during the 10 weeks of project implementation who
presented with a diagnosis of chronic pain resulting in 222 total visits. Of these patient visits 210
(96%) were assessed by the provider, 186 (84%) completed a screening tool, 207 (93%)
underwent urine drug screening, 222 (100%) completed a treatment agreement, 207 (93%)
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received education material on opioid medications, and 154 (69%) had the PDMP database
accessed prior to prescribing opioid medication; this compares to the pre-intervention group of
patients, consisting of 236 total visits and 157 unique patients, who were assessed by the
provider 225 (95%), completed the screening tool 0 (0%), completed a urine drug screen 177
(75%), completed a treatment agreement 189 (80%), received education on opioid medications
213 (90%), and had the PDMP accessed to check for previous opioid prescriptions 12 (5%)
(Figure 1).

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Pre-Interven4on
Post-Interven4on

Figure 1. Pre- and post-intervention utilization of CDC's guidelines.
A Fisher’s exact test was performed, including both pre-intervention and postintervention data, to examine the relationship between implementation of all six CDC guidelines
and referral to a pain management specialist for treatment of CNCP. Applying Fishers exact test,
the number of patients referred to pain management are significantly higher (p = .001) when all
six CDC guidelines are used (Table 4). The results are statistically significant when p < .005.
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Table 4
Fisher’s Exact Test: Relationship Between Implementation of All Six of the CDC Guidelines
and Referral to Pain Management

Value

df

Asymptotic
Significance
(2-sided)

Continuity Correction a

12.473

1

.001

Likelihood Ratio

11.657

1

.001

Fisher's Exact Test
Linear-by-Linear
Association

12.446

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.001

.001

.000

N of Valid Cases
458
Note. a. Computed only for a 2x2 table
A chi-square test of independence was performed, including both pre-intervention and
post-intervention data, to examine the relationship between implementation of CDC guidelines
and the number of opioid pain medication prescriptions being written for treatment of CNCP.
The relationship between these variables was significant, χ2 (1, 458) = 38.11, p < .05 (Table 5).
Utilization of all tools recommended by the CDC increased on subsequent visits for five
of the six tools. Use of the screening tool went from 81% on the first visit post-intervention to 88
% by the third visit, use of the treatment agreement stayed at 100% from the first visit postintervention to the third visit post-intervention, use of the educational handout went from 92%
from the first visit post-intervention to 100% by the third visit post-intervention, utilization of
urine drug screening went from 91% on the first visit post-intervention to 98% by the third visit
post-intervention and documentation of provider assessment of need increased from 92% on the
first visit post-intervention to 100% by the third visit post-intervention. Accessing the PDMP
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Table 5
Chi-square: Relationship Between Implementation of All Six of the CDC Guidelines and
Number of Opioid Prescriptions Written

Value

df

Asymptotic
Significance
(2-sided)

Pearson Chi-Square

38.109a

1

.000*

Continuity Correctionb

35.342

1

.000

Likelihood Ratio

37.094

1

.000

Fisher's Exact Test
Linear-by-Linear
Association

38.026

N of Valid Cases

458

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.000

.000

.000

Note. a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 8.34.
b. Computed only for a 2x2 table
* Statistically significant when p < .05
decreased from 73% on the first visit post-intervention to 41% by the third visit postintervention. Reported reasons for this decrease in accessing the PDMP included:
•

“I know this patient.”

•

“I did not have time.”

•

“I did not think it was necessary.”

Accessing the PDMP and having the patient fill out the screening tool for potential abuse
proved to have significance in determining which patients received opioid pain medications and
which were referred to pain management, while use of the urine drug screen was significant for
deciding on giving a prescription for opioid pain medications. A chi-square test of independence
was performed, including both pre-intervention and post-intervention data, to examine the
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relationship between utilization of PDMP and the number of opioid pain medication

prescriptions being written for treatment of CNCP. The relationship between these variables was
significant, χ2 (1, 458) = 31.77, p < .05 (Table 6).
Table 6
Chi-square: Relationship Between Utilization of the PDMP and Receiving an Opioid Medication
Prescription

Value

df

Asymptotic
Significance
(2-sided)

Pearson Chi-Square

31.770 a

1

.000*

Continuity Correctionb

29.311

1

.000

Likelihood Ratio

32.450

1

.000

Fisher's Exact Test
Linear-by-Linear
Association

31.700

N of Valid Cases

458

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.000

.000

.000

Note. a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 8.34.
b. Computed only for a 2.2 table
* Statistically significant when p < .05
Use of PDMPs leads to lower opioid prescription rates, decreases provider shopping, and
reduces rates of opioid poisoning (Compton et al., 2015, Dowell et al., 2016). A Fisher’s exact
test was performed, including both pre-intervention and post-intervention data, to examine the
relationship between accessing the PDMP and referral to a pain management specialist for
treatment of CNCP. Applying Fisher’s exact test, the number of patients referred to pain
management are significantly higher (p =.002) when PDMP is accessed (Table 7). The results
are considered significant when p < .005.
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Table 7
Fisher’s Exact Test: Relationship Between Utilization of the PDMP and Referral to
Pain Management for treatment of CNCP.

Value

df

Asymptotic
Significance
(2-sided)

Continuity Correctiona

8.120

1

.004

Likelihood Ratio

9.882

1

.002

Fishers Exact Test
Linear-by-Linear
Association

10.108

N of Valid Cases

458

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.002

.002

.001

Note. a. Computed only for a 2x2 table
A chi-square test of independence was performed, including both pre-intervention and
post-intervention data, to examine the relationship between utilization of the screening tool and
the number of opioid pain medication prescriptions being written for treatment of CNCP. The
relationship between these variables was significant, χ2 (1, 458) = 35.41, p < .05 (Table 8).
A Fisher’s exact test was performed, including both pre-intervention and postintervention data, to examine the relationship between utilization of the screening tool and
referral to a pain management specialist for treatment of CNCP. Applying Fishers exact test, the
number of patients referred to pain management are significantly higher (p =.000) when the
screening tool is accessed (Table 9). The results are considered significant when p < .005.
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Table 8
Chi-square: Relationship Between Utilization of the Screening Tool and Receiving an Opioid
Medication Prescription.

Value

df

Pearson Chi-Square

35.413a

1

Asymptotic
Significance
(2-sided)
.000*

Continuity Correctionb

32.868

1

.000

Likelihood Ratio

43.246

1

.000

Fisher's Exact Test
Linear-by-Linear
Association

35.335

N of Valid Cases

458

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.000

.000

.000

Note. a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.34.
b. Computed only for a 2x2 table
* Statistically significant when p < .05
Table 9
Fisher’s Exact Test: Relationship Between Utilization of the Screening Tool and Referral to
Pain
Management for treatment of CNCP.
Value

df

Continuity Correctiona

14.055

1

Asymptotic
Significance
(2-sided)
.000

Likelihood Ratio

20.222

1

.000

Fisher's Exact Test
Linear-by-Linear
Association

16.446

N of Valid Cases

458

Note. a. Computed only for a 2x2 table

1

.000

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.000

.000
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Urine drug screening can provide information on drug use not reported by patients and

can also help to identify those patients who are potentially diverting drugs (Volkow & McLellan,
2016). A Fisher’s exact test was performed, including both pre-intervention and postintervention data, to examine the relationship between utilization of urine drug screening and
receiving an opioid medication prescription for treatment of CNCP. Applying Fishers exact test,
the number of patients who received pain medication were significantly higher (p =.036) when
the screening tool is accessed (Table 10). The results are considered significant when p < .005.
Table 10
Fisher’s Exact Test: Relationship Between Utilization of Urine Drug Screening and Receiving
an Opioid Medication Prescription.
Value

df

Continuity Correctiona

3.495

1

Asymptotic
Significance
(2-sided)
.062

Likelihood Ratio

8.338

1

.004

Fisher's Exact Test
Linear-by-Linear
Association

4.656

N of Valid Cases

458

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.036

.016

.031

Note. A. Computed only for a 2x2 table
While these tools were significant in the relationship between determining which patients
were referred to pain management and which received prescriptions for opioid medications, one
co-morbid condition stands out as significant in determining which patients were referred to pain
management and which received a prescription for opioid pain medication. A Fisher’s exact test
was performed, including both pre-intervention and post-intervention data, to examine the
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relationship between depression and referral to pain management for treatment of CNCP.

Applying Fishers exact test, the number of patients who were referred to pain management was
significantly higher (p =.036) when a diagnosis of depression is also present (Table 11). The
results are considered significant when p < .005.
Table 11
Fisher’s Exact Test: Relationship Between Depression and Referral to Pain Management for
Treatment of CNCP.
Value

df

Continuity Correctiona

3.725

1

Asymptotic
Significance
(2-sided)
.054

Likelihood Ratio

4.278

1

.039

Fishers Exact Test
Linear-by-Linear
Association

5.382

N of Valid Cases

458

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.036

.036

.020

Note. a. Computed only for a 2x2 table
Depression and post-traumatic stress disorder have been found to be prevalent in patients
seeking treatment for pain (Seal, Becker, Tighe, Li, & Rife, 2017). A Fisher’s exact test was
performed, including both pre-intervention and post-intervention data, to examine the
relationship between depression and receiving an opioid medication prescription for treatment of
CNCP. Applying Fishers exact test, the number of patients who received pain medication and
were diagnosed with depression were significantly higher (p =.023) when also diagnosed with
depression (Table 12). The results are considered significant when p < .005.
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Table 12
Fisher’s Exact Test: Relationship Between Depression and Receiving an Opioid
Medication Prescription.
Value

df

Continuity Correctiona

5.423

1

Asymptotic
Significance
(2-sided)
.020

Likelihood Ratio

5.621

1

.018

Fishers Exact Test
Linear-by-Linear

6.765

1

Exact Sig
(2-sided)

Exact Sig
(1-sided)

.023

.015

.009

Association
N of Valid Cases

458

Note. a. Computed only for a 2x2 table
Discussion
Implementation of the full guidelines had significant impact on the number of
prescriptions written for opioid pain medications for patients seeking treatment for CNCP and
also impacted the number of patients referred to a pain management specialist for treatment of
CNCP. Increases in treatment agreements from 80% of patients to 100% of patients, urine drug
screens from 75% of patients to 93% of patients, screening tools for potential abuse from 0% of
patients to 84% of patients, a documented provider assessment from 95% of patients to 96% of
patients, accessing the PDMP from 5% of patients to 69% of patients, and documentation of
education from 90% of patients to 93% of patients resulted in11 patients (7%) being referred to
pain management and also resulted in 23 prescriptions (10%) not being written for opioids for
CNCP. No studies have been identified that tested the validity of use of all six interventions
contained in the CCD guidelines. In a study by Chen et al. (2016), the number of prescriptions
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written for opioids for the treatment of CNCP decreased by 12.9% in a primary care clinic in the
San Francisco Bay Area after implementing several of the tools recommended by the CDC. The
study by Chen et al. (2016), had a patient population of 54% male, 50% White, 23% Asian, and
4% Black. This compares to the clinic in San Antonio which was 52% male, 73% White nonHispanic, 20% Hispanic, and 7% Black. Chen et al. (2016), found that disseminating the CDC
guidelines to providers had significant impact on the number of urine drug screens ordered.
While many of the goals were achieved, the goal of accessing the PDMP at least 80% of
the time was not achieved. The providers at the clinic only accessed the PDMP 69% of the time
it was indicated. Reasons providers expressed for not accessing the PDMP included not “having
time,” “thinking it was not necessary, ” and “I know my patient.” These same reasons are
detailed in a qualitative study discussing how primary care physicians decide when to prescribe
opioids. The study by Harle et al. (2015) demonstrated that trust and familiarity were key
determinates whether a provider wrote a prescription for opioid medications. In this study, the
researcher found that the more often the patient visited a provider for chronic pain, the less likely
the provider would access the PDMP. On the first visit post-intervention implementation, 73% of
patients had the PDMP accessed to determine the frequency of opioid prescriptions, by the third
visit of these patients, just 41% had the PDMP accessed.
Depression was prevalent in 20% of the patients seeking treatment for CNCP (Table 1)
and had significant influence on if that patient was referred to pain management or received a
prescription for opioid medication (Tables 11 & 12). Depression and post-traumatic stress
disorder were found to be prevalent in a group of patients seeking treatment at the Veterans
Administration facility in San Francisco (Seal, Becker, Tighe, Li, & Rife, 2017), while in a study
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conducted at the Mayo Clinic by Philpot et al. (2017) found depression to be prevalent in 36% of
patients receiving opioids for treatment of CNCP.
Full implementation of the CDC guidelines would not have happened without the
commitment of the entire team working at the clinic. Both providers and medical assistants
increased communication between themselves and the patients on the needs, dangers, and good
stewardship required of prescribing opioid medications. The medical assistants proved
instrumental in making sure all forms were utilized, urine drug screens were done, and that
patients received the educational flyer. The providers were responsible for reviewing the
screening tool and treatment agreement, documenting an assessment of need, accessing the
PDMP, and interpreting the urine drug screens. During one on one meetings with the providers,
and bi-weekly meetings with all staff, reminders were given to all about the need for following
the guidelines and use of all the tools available to ensure adherence. These meetings served as
motivation for continued improvement and facilitated real-time feedback on progress and hurdles
being encountered.
Limitations
This study was conducted over a relatively short period, 10 weeks does not give adequate
time to implement a set of interventions and adequately allow for the learning curve that
accompanies any new initiative. A longer study period may have increased compliance even
more and resulted in even fewer prescriptions being written or more patients being referred to
pain management.
In addition, the racial breakdown of the patient population does not reflect that of society
as a whole. With 73% of the patient population being White non-Hispanic, it missed many
potential patients who belong to marginalized, vulnerable, or underserved populations. This
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evidence-based practice project was based in one clinic in Northern San Antonio, Texas and was
limited in its reach to diverse areas or populations.
Recommendations
Pre-intervention data showed the clinic was well behind in the full implementation of the
CDC’s guidelines for prescribing opioid medications for CNCP indicating a need for an
evidence-based practice improvement project to improve prescription practices of opioids in the
primary care setting. Some interventions in the CDC’s guidelines were already in practice at the
clinic, two of the recommended interventions were either not used or were infrequently used.
Further investigation into resistance to access the PDMP needs to be explored. This tool shows
high significance in determining if a patient should be referred to pain management or if they
should be given a prescription for an opioid pain medication (Tables 6 & 7).
Implications for Practice
Treating patients with CNCP has many challenges and potential pitfalls. This project has
many implications to help identify patients with chronic pain, determine the appropriate
treatment location, and reduce the number of opioid pain medication prescriptions written that
may be inappropriate. With over 16,000 deaths each year from the misuse of prescription opioid
medications, these interventions need to be implemented to protect patients from unneeded
opioid medications.
While this project was implemented in an internal medicine practice setting and focused
on adults seeking treatment for chronic pain, these interventions and guidelines could be
implemented in a host of specialty settings where patients might have complaints of chronic
pain. Advanced Practice Registered Nurses trained at the Doctoral level possess unique clinical
and leadership skills that allows implementation of evidence gained through research.
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Conclusion
The use and misuse of opioid pain medication has reached epidemic proportions in the
United States. More than 16,000 people die each year due to the misuse or abuse of prescription
opioid medications, which is more than from heroin, cocaine, and benzodiazepines combined.
The purpose of this evidence-based practice project was to establish processes enabling a
primary care clinic to implement and adhere to the 2016 Centers for Disease Control’s guidelines
for opioid prescription practices in the primary care setting.
Implementation of the CDC’s 2016 guidelines, led to an increase in: proper screening of
patients seeking treatment for CNCP (84%), a complete assessment of patients seeking treatment
for CNCP (96%), a thorough education of patients being treated for CNCP (93%), providers
accessing the PDMP (69%), performing urine drug screens to assess patients for compliance
(93%), and having the patient complete a treatment agreement (100%). The implementation of
these guidelines has led to 11 (7%) patients referred to a pain management specialist and a 10%
reduction in the number of prescriptions written for opioid pain medications for patients seeking
treatment for chronic pain.
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